Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

9821	Companies
197090	Keywords
128169	Articles
104821	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 12/05/2024 at 14:45, 1 year 2 months ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Xenetic Biosciences partners with PeriNess to advance clinical proof-of-concept studies for systemic DNase I treatment in pancreatic and colorectal cancers. Collaboration aims to leverage expertize and improve therapeutic responses

Xenetic Biosciences Clinical Development Pancreatic Cancer PeriNess Systemic DNase I
BRIEF

published on 11/22/2024 at 15:20, 1 year 2 months ago

Xenetic Biosciences Shares Insights on DNase I Efficacy in Cancer Treatment

Xenetic Biosciences Cancer Treatment Preclinical Data DNase I Immune Checkpoint Blockade
BRIEF

published on 11/22/2024 at 15:20, 1 year 2 months ago

Xenetic Biosciences partage ses connaissances sur l'efficacité de la DNase I dans le traitement du cancer

Traitement Du Cancer Biosciences Xénétiques Données Précliniques ADNase I Blocage Du Point De Contrôle Immunitaire
PRESS RELEASE

published on 11/22/2024 at 15:15, 1 year 2 months ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, presents positive preclinical data at SITC 39th Annual Meeting. Focus on advancing immune-oncology technologies to treat hard cancers

Cancer Treatment Preclinical Data Immunotherapy SITC 39th Annual Meeting Dr. Reid Bissonnette
BRIEF

published on 11/21/2024 at 14:35, 1 year 2 months ago

Xenetic Biosciences annonce des résultats précliniques prometteurs pour la thérapie par ADNase I et cellules CAR T dans le mélanome

Étude Préclinique Mélanome ADNase I Cellules CAR-T Thérapie Oncologique
BRIEF

published on 11/21/2024 at 14:35, 1 year 2 months ago

Xenetic Biosciences Reports Promising Preclinical Results for DNase I and CAR T Cell Therapy in Melanoma

Preclinical Study Melanoma DNase I CAR T Cells Oncology Therapy
PRESS RELEASE

published on 11/21/2024 at 14:30, 1 year 2 months ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic presents preclinical data on DNase I and CAR T cells' synergistic effects in treating solid tumors. Results show promise in modulating tumor microenvironment and enhancing therapeutic responses

Preclinical Data Solid Tumors Xenetic DNase I CAR T Cells
BRIEF

published on 11/13/2024 at 14:35, 1 year 2 months ago

Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2024

Résultats Financiers Développement Clinique Biosciences Xénétiques Plateforme D'oncologie DNase Partenariats Institutionnels
BRIEF

published on 11/13/2024 at 14:35, 1 year 2 months ago

Xenetic Biosciences Reports Q3 2024 Financial Results

Financial Results Xenetic Biosciences Clinical Development DNase Oncology Platform Institutional Partnerships
PRESS RELEASE

published on 11/13/2024 at 14:30, 1 year 2 months ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Xenetic Biosciences reports Q3 2024 financial results, progress in DNase-based platform for oncology, partnership with institutional collaborators, and $6.8 million cash balance

Xenetic Biosciences Oncology Q3 2024 Financial Results Institutional Partnerships DNase-based Platform

Accesswire

Published on 02/07/2026 at 01:00, 20 hours ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 21 hours 50 minutes ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 22 hours 59 minutes ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 5 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 7 hours ago

Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 16:35, 4 hours 24 minutes ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 4 hours 39 minutes ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 1 hour ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 3 hours ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 17:40, 1 day 3 hours ago

Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.01.26.

Les Echos

Published on 02/06/2026 at 18:22, 1 day 2 hours ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 1 day 2 hours ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 4 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 1 day 4 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 1 day 13 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE